** Shares of biotech firm Oragenics OGEN.A fall 53% to $1.80 premarket
** OGEN is raising up to $20 million through a public offering of preferred stock and warrants
** The offering includes up to 800,000 shares of Series H Convertible Preferred Stock and warrants to buy 800,000 more shares
** Each unit of preferred stock and a warrant is priced at $25
** The preferred stock can be converted into common stock at $2.50/share, a 34.6% discount to the stock's last close
** Co has 715,843 outstanding shares with a market cap of $2.73 million - LSEG
** Co says the proceeds will fund concussion clinical trials, repay a $3 million bridge note, and support general corporate needs
** Dawson James Securities is managing the offering
** As of last close, stock down 65.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.